BridgeBio Pharma (NASDAQ:BBIO) Director Jennifer Cook Sells 37,167 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Jennifer Cook sold 37,167 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $70.00, for a total value of $2,601,690.00. Following the completion of the transaction, the director directly owned 8,383 shares in the company, valued at $586,810. The trade was a 81.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

BridgeBio Pharma Stock Up 0.9%

NASDAQ BBIO opened at $69.26 on Thursday. BridgeBio Pharma, Inc. has a 52 week low of $41.80 and a 52 week high of $84.94. The firm has a market capitalization of $13.56 billion, a P/E ratio of -18.52 and a beta of 0.97. The company has a 50-day moving average price of $69.20 and a 200-day moving average price of $71.86.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. The firm’s revenue for the quarter was up 66.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.88) EPS. As a group, equities research analysts anticipate that BridgeBio Pharma, Inc. will post -2.29 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BBIO shares. Weiss Ratings reiterated a “sell (d)” rating on shares of BridgeBio Pharma in a research note on Friday, May 15th. HC Wainwright restated a “buy” rating and issued a $110.00 price objective on shares of BridgeBio Pharma in a research note on Thursday, May 28th. JPMorgan Chase & Co. raised their target price on BridgeBio Pharma from $89.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, March 10th. Oppenheimer decreased their target price on BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Finally, Canaccord Genuity Group began coverage on BridgeBio Pharma in a research report on Wednesday, June 3rd. They set a “buy” rating and a $104.00 target price on the stock. Twenty-one investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, BridgeBio Pharma presently has a consensus rating of “Moderate Buy” and an average target price of $92.90.

Hedge Funds Weigh In On BridgeBio Pharma

Several large investors have recently added to or reduced their stakes in BBIO. Aster Capital Management DIFC Ltd purchased a new stake in shares of BridgeBio Pharma in the third quarter worth $31,000. Harvest Fund Management Co. Ltd bought a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at $34,000. Jones Financial Companies Lllp purchased a new position in shares of BridgeBio Pharma during the 1st quarter valued at $35,000. Huntington National Bank lifted its stake in shares of BridgeBio Pharma by 111.7% during the 3rd quarter. Huntington National Bank now owns 743 shares of the company’s stock valued at $39,000 after buying an additional 392 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in BridgeBio Pharma by 91.4% in the 4th quarter. Farther Finance Advisors LLC now owns 513 shares of the company’s stock worth $39,000 after buying an additional 245 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.